Clinical Trials
CureVac’s COVID-19 Vaccine Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced the publication of preclinical data...
Clinical Trials
Dr Reddy’s Laboratories gets approval for phase 3 trials of Sputnik V Covid vaccine
Dr Reddy’s Laboratories (DRL) on Monday announced the start of its phase 3 clinical trial of Russia's Sputnik V Covid-19 vaccine after receiving clearance from...
Clinical Trials
ICON supports Pfizer and BioNTech on the investigational COVID-19 vaccine trial
ICON plc,a global provider of outsourced drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries and government and public...
Clinical Trials
Phesi and Sensyne Health Agree Collaboration to Advance Development of Synthetic Arms in Clinical Trials
Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, announced it has entered into an exclusive strategic collaboration with clinical AI...
Clinical Trials
Bharat Biotech vaccine approved in clinical trial mode, consent of participants has to be taken: ICMR
Balram Bhargava, chief of Indian Council of Medical Research (ICMR), said on Tuesday that Bharat Biotech’s Covid-19 vaccine has been cleared in the clinical trial...
Clinical Trials
Tiziana Life Sciences completes clinical trial of nasally administered Foralumab to treat COVID-19 in Brazil
Tiziana Life Sciences announced the completion of its clinical study in Brazil investigating nasally administered Foralumab, its proprietary human monoclonal antibody, either alone or in...
Clinical Trials
AbbVie, Boehringers Skyrizi yields positive results in Phase III psoriatic arthritis trials
AbbVie reported data from a pair of Phase III studies showing that Skyrizi (risankizumab) led to significantly more psoriatic arthritis patients achieving the primary endpoint...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.